#1 Clinical Trials Search in Europe
EU – Europe
AT – Austria
HR – Croatia
CZ – Czech Republic
DK – Denmark
EE – Estonia
FI – Finland
FR – France
DE – Germany
IS – Iceland
IT – Italy
LV – Latvia
LT – Lithuania
NL – Netherlands
NO – Norway
PL – Poland
PT – Portugal
RO – Romania
SK – Slovakia
SI – Slovenia
ES – Spain
SE – Sweden
  • Find a Clinical Trial

    Search Trials by Disease

    Non-small cell lung cancer Breast cancer Plasma cell myeloma Neoplasm Acute myeloid leukaemia Neoplasm malignant Colitis ulcerative Obesity Colorectal cancer metastatic Prostate cancer Crohn's disease Ovarian cancer Colorectal cancer Hepatocellular carcinoma Dermatitis atopic Dementia Alzheimer's type Asthma Type 2 diabetes mellitus Breast cancer metastatic Non-small cell lung cancer metastatic More trials…
  • Rare Diseases Treatments

    Search Trials by Disease

    Leukodystrophy Trigeminal neuralgia Short stature Alternating hemiplegia of childhood B precursor type acute leukaemia Bladder cancer Colitis ulcerative Endometrial cancer recurrent Malignant oligodendroglioma Acute lymphocytic leukaemia recurrent Mucous membrane pemphigoid Small intestine leiomyosarcoma Spinal muscular atrophy Pseudomyxoma peritonei Canavan disease More trials…

    Learn about Rare Diseases

    Proteus syndrome – Diagnostics Congenital generalised lipodystrophy – Basic Information Mucopolysaccharidosis III – Trials in Disease Biotinidase deficiency – Diagnostics Medulloblastoma recurrent – Basic Information Primary biliary cholangitis – Diagnostics Behcet’s syndrome – Treatment Skin angiosarcoma – Life with Disease Activated PI3 kinase delta syndrome – Trials in Disease X-linked lymphoproliferative syndrome – Life with Disease More diseases
  • Vaccine Clinical Trials
  • Pediatric Clinical Trials
  • Resources for Patients

    Browse Innovative Treatments

    Valiltramiprosate Cerebrolysin Concentrate Rbl016.2 Ecopipam Hydrochloride Etelcalcetide The-630 Parsaclisib Hydrochloride Levocabastine Hydrochloride Lacnotuzumab Pristinamycin Doconexent Skb264 Efanesoctocog Alfa Ketotifen Hydrogen Fumarate Hct116-A Lisaftoclax Streptococcus Agalactiae ANX007 Clarithromycin Cytisinicline More therapies…

    Learn about Your Condition

    Lumbosacral radiculopathy Drug use disorder Myotonia Anal squamous cell carcinoma Nephrotic syndrome Hypertonic bladder Autoimmune disorder B-cell lymphoma recurrent Procedural hypotension Type V hyperlipidaemia Systemic infection Spinal muscular atrophy Albuminuria Fibrosarcoma Colitis ulcerative More diseases
  • Healthy Volunteers
  • Patient Guide
  • Our Partners
  • About Us
  • Contact us
  • Region
    🇪🇺 Europe
    🇦🇹 Austria
    🇭🇷 Croatia
    🇨🇿 Czech Republic
    🇩🇰 Denmark
    🇪🇪 Estonia
    🇫🇮 Finland
    🇫🇷 France
    🇩🇪 Germany
    🇮🇸 Iceland
    🇮🇹 Italy
    🇱🇻 Latvia
    🇱🇹 Lithuania
    🇳🇱 Netherlands
    🇳🇴 Norway
    🇵🇱 Poland
    🇵🇹 Portugal
    🇷🇴 Romania
    🇸🇰 Slovakia
    🇸🇮 Slovenia
    🇪🇸 Spain
    🇸🇪 Sweden
  1. Clinicaltrials.eu/
  2. Centre Hospitalier Departemental Vendee

Centre Hospitalier Departemental Vendee

Boulevard Stephane Moreau, La Roche sur Yon, 85925, France

Want to learn more about this study or check if you can participate? Contact us.

  • Study of Fuzuloparib, Abiraterone Acetate, and Prednisone for First-Line Treatment in Patients with Metastatic Castration-Resistant Prostate Cancer

    Not recruiting

    3 1 1
    Investigated Diseases:
    • Hormone-refractory prostate cancer
    • Prostate cancer
    • Prostate cancer metastatic
    Investigated Drugs:
    • 4-((3-((5,6-Dihydro-2-(Trifluoromethyl)(1,2,4)Triazolo(1,5-A)Pyrazin-7(8H)-Yl)Carbonyl)-4-Fluorophenyl)Methyl)-1(2H)-Phthalazinone
    • Abiraterone Acetate
    • Prednisone
    Belgium Czechia France Hungary Poland Spain

  • Study of rituximab and belimumab combination compared to rituximab alone in adults with persistent or chronic immune thrombocytopenia (ITP)

    Not recruiting

    3 1 1
    Investigated Drugs:
    • Belimumab
    France

  • Study Comparing Lenalidomide, Daratumumab, and Dexamethasone for Frail Patients with Untreated Multiple Myeloma Not Eligible for High-Dose Therapy

    Not recruiting

    3 1 1 1
    Investigated Diseases:
    • Plasma cell myeloma
    Investigated Drugs:
    • Daratumumab
    • Dexamethasone
    • Lenalidomide
    Belgium France

  • Study of PF-07220060 and Fulvestrant for Adults with Advanced or Metastatic HR-positive, HER2-negative Breast Cancer After Previous Treatment

    Not recruiting

    3 1 1 1
    Investigated Diseases:
    • Breast cancer
    • Breast cancer metastatic
    Investigated Drugs:
    • Everolimus
    • Exemestane
    • Fulvestrant
    Belgium Bulgaria Czechia Denmark Finland France +8

  • Study on Enzalutamide and Leuprorelin Acetate for Men with High-Risk Nonmetastatic Prostate Cancer After Treatment

    Not recruiting

    3 1 1
    Investigated Diseases:
    • Prostate cancer
    Investigated Drugs:
    • Enzalutamide
    • Leuprorelin Acetate
    Austria Denmark Finland France Italy The Netherlands +4

  • Study on Adding Nivolumab to Cisplatin and Radiotherapy for High-Risk Patients with Head and Neck Squamous Cell Carcinoma

    Not recruiting

    3 1 1 1
    Investigated Diseases:
    • Squamous cell carcinoma of head and neck
    Investigated Drugs:
    • Cisplatin
    • Nivolumab
    Belgium France Greece Poland Spain

  • Study on Reduced Dose Intensity of Pembrolizumab and Drug Combination for Patients with Advanced or Metastatic Cancer Responding to Standard Immunotherapy

    Not recruiting

    3 1 1 1
    Investigated Diseases:
    • Bladder cancer
    • Colorectal cancer
    • Head and neck cancer
    Investigated Drugs:
    • Atezolizumab
    • Avelumab
    • Cemiplimab
    France

  • Study comparing iberdomide, daratumumab and dexamethasone versus daratumumab, bortezomib and dexamethasone in patients with relapsed or refractory multiple myeloma

    Not recruiting

    3 1 1 1
    Investigated Diseases:
    • Plasma cell myeloma
    Investigated Drugs:
    • Bortezomib
    • Daratumumab
    • Dexamethasone
    Austria Belgium Czechia Denmark Finland France +10

  • Study of Pembrolizumab with Drug Combination for Patients with Microsatellite Stable Metastatic Colorectal Cancer with High Immune Infiltrate

    Not recruiting

    2 1 1 1
    Investigated Diseases:
    • Colorectal cancer metastatic
    Investigated Drugs:
    • Bevacizumab
    • Capecitabine
    • Fluorouracil
    France

  • Study on Apalutamide with Radiotherapy and Hormone Therapy for High-Risk Prostate Cancer Patients with Rising PSA After Surgery

    Not recruiting

    3 1 1
    Investigated Diseases:
    • Prostate cancer
    Investigated Drugs:
    • Apalutamide
    France
Previous Page
1 … 11 12 13 14 15 … 21
Next Page

European Clinical Trials Information Network

The European Clinical Trials Information Network is transforming access to clinical trial information for patients across Europe. By overcoming language barriers, our platform allows everyone, regardless of their native language, to easily find relevant and comprehensible clinical trial data. This innovative service connects patients to cutting-edge treatments, creating a unified European community where health and progress transcend borders.

This service is not affiliated with the European Commission, the EMA, or the official CTIS system. Most information comes from publicly available international clinical-trial registries, supplemented by data from academic centres, national regulators, and commercial sponsors. We aim to keep all content accurate and up to date.

Explore the full ecosystem of clinical research in Europe.

The information provided on this website is mainly derived from international public clinical trial databases (CTIS.eu). In addition, we are including supplementary sources, such as information provided by academic centers and national regulators, as well as information supplied by commercial sponsors (pharmaceutical companies and contract research organizations). We try to ensure that the information provided is accurate and up to date.

Certain content and visual elements on this website have been generated or enhanced using artificial intelligence (AI).

The website is published by:
CTIN POLAND sp. z o.o.
with its registered office in Warsaw,
ul. rtm. Witolda Pileckiego 67/109,
02-781 Warsaw, Poland,
entered in the Register of Entrepreneurs of the National Court Register under KRS number 0001111334,
REGON: 528919042, NIP (Tax ID): 9512598637
Contact us

© 2026 CTIN Poland

Privacy Policy

Terms and Conditions

Contact

For Sites and Sponsors

Clinical Trial Locations

We use cookies

The website uses cookies to ensure the proper functioning of the site and to analyze internet traffic. Some cookies are essential for using the service and do not require consent. You can accept all cookies or use only the essential ones. Data is processed in accordance with our Privacy Policy. You have the right to withdraw your consent, access, rectify, delete, or limit the processing of your data at any time.
Numer nieprawidłowy!
Numer nieprawidłowy!